A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer
Latest Information Update: 15 Aug 2025
At a glance
Most Recent Events
- 11 Jul 2025 Number of treatment arms increased from 7 to 8 by the addition of "Experimental: Part 2 Cohort 4 - Selected dose level of BNT323 + BNT327" arm.
- 11 Jul 2025 Planned number of patients changed from 320 to 380.
- 11 Jul 2025 Planned End Date changed from 1 Sep 2032 to 1 May 2029.